Please login to the form below
esketamine
This page shows the latest esketamine news and features for those working in and with pharma, biotech and healthcare.
NICE knocks back J&J’s depression nasal spray Spravato
Spravato (esketamine) is a glutamate NMDA receptor modulator – when it was first approved by the FDA in March last year it was quickly hailed as an end to a drought in ... Meindert Boysen, director of the centre for health technology evaluation at NICE
Latest news
-
J&J gets EU approval for depression nasal spray Spravato
J&J’s pharma division Janssen says Spravato (esketamine) is the first antidepressant medicine with a new mechanism of action to reach the European market in more than 30 years. ... Esketamine is a glutamate NMDA receptor modulator, and is of
-
Sage slides off a MOUNTAIN as depression drug flunks trial
Johnson &Johnson is the first company to score an approval in this category, getting and FDA green light earlier this year for glutamate NMDA receptor modulator Spravato (esketamine), a nasal spray
-
J&J’s ponesimiod tops Aubagio in head-to-head MS trial
The company does however have a resurgent central nervous system (CNS) therapeutic category following the approval of Spravato(esketamine), a nasal spray for treatment-resistant depression that J&J reckons can
-
Stung by critics, J&J says antidepressant Spravato saves money
The drugmaker has reported a new analysis which suggests that adding Spravato (esketamine) to background oral therapy cost at least $20, 000 less per patient in those achieving remission than patients ... Esketamine is a glutamate NMDA receptor modulator,
-
Depression drug failure adds to Allergan's woes
The misfiring of rapastinel is a major blow for the company’s most important late-stage candidate, and is a clear contrast to J&J’s rival treatment Spravato (esketamine), which
More from news
Approximately 3 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
War on drugs: the use of controlled substances in medicine
Ketamine has shown efficacy in the treatment of mental health conditions with the FDA approving a version of it, esketamine nasal spray, in March 2019 for treatment-resistant depression.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- COVID-19 could be key in identifying viruses with pandemic potential
- Novo Nordisk Foundation commits €127m for new cell therapy facility
- Alzheimer’s Research UK launches ‘Change The Ending’ campaign
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
No results were found
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
